Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ESC working groups bring experts in their fields to provide education, share expertise and facilitate exchanges about best practices and ongoing medical developments.
An intense three-day scientific programme will update you on basic science, translational medicine and clinical practice in the areas of thrombosis, aorta and peripheral vascular diseases.
10/10/2024 11:3012/10/2024 13:00Europe/ParisEuroThrombosis and EuroVessels 2024
EuroCVP - The annual scientific meeting of the ESC Working Group on Cardiovascular Pharmacotherapy (ESC WG CVP) will be held on 7 - 9 November 2024 in Budapest, Hungary.
Every year the Working Group on Cardiovascular Pharmacotherapy organises EuroCVP Meeting to gather pharmacologists, pharmacists, research nurses and personnel, as well as general cardiologists with an interest in cardiovascular pharmacotherapy, pharmacology and heart failure.
All cardiologists are concerned by pharmacology and drugs therapy, thus, they should all participate and contribute to EuroCVP.
During the meeting, focus is made on key treatment breakthroughs, clinical applicability and significance of new drugs and new data. Since 2015, a Clinical Trials Workshop is held in conjunction to the main conference to give a focused view of the clinical trial arena, including trial methodology, trial challenges, trial interpretation and analysis, regulatory issues and good clinical practice.
This “talk show” format event is to underline the main cardio-reno-metabolic protective effects of SGLT2i, the mechanism and the limits of our knowledge.
Learning objectives: - Understand and interpret the specific clinical benefit and safety of SGLT2i - Understand the subtle mechanisms of action - Understand the limits of knowledge and future directions of research
26/11/2024 17:0026/11/2024 18:15Europe/ParisWorking Group Talk "SGLT2i : from bench to bedside. What we know, what we don’t know, and what we should know"
Our mission: To reduce the burden of cardiovascular disease.